Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (22)

2018

  1. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

2014

  1. Oncological translational research in the Spanish national health system: The INTRO study

    Clinical and Translational Oncology, Vol. 16, Núm. 8, pp. 686-695

  2. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

2011

  1. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer

    Journal of Thoracic Oncology, Vol. 6, Núm. 2, pp. 286-290

  2. Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

    Lung Cancer, Vol. 74, Núm. 2, pp. 326-331

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2009

  1. Professional burnout among Spanish medical oncologists

    Clinical and Translational Oncology, Vol. 11, Núm. 2, pp. 86-90

  2. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

2006

  1. Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications

    Lung Cancer, Vol. 52, Núm. 3, pp. 343-347

  2. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675

  3. Quantification in the serum of the catalytic fraction of reverse telomerase: A useful prognostic factor in advanced non-small cell lung cancer

    Anticancer Research, Vol. 26, Núm. 6 C, pp. 4905-4909

2005

  1. 14-3-3σ methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group

    Journal of Clinical Oncology, Vol. 23, Núm. 36, pp. 9105-9112

  2. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086

  3. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

    Lung Cancer, Vol. 50, Núm. 3, pp. 339-346

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

  2. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

    Clinical Cancer Research, Vol. 10, Núm. 4, pp. 1318-1325

  3. Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203

2003

  1. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients

    Clinical Lung Cancer, Vol. 4, Núm. 4, pp. 237-241

2002

  1. Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer

    Clinical Cancer Research, Vol. 8, Núm. 7, pp. 2286-2291

  2. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: An active and low toxicity regimen

    European Journal of Cancer, Vol. 38, Núm. 9, pp. 1204-1211